TY - JOUR
T1 - Biomarkers in Duchenne Muscular Dystrophy
AU - Lee-Gannon, Theo
AU - Jiang, Xuan
AU - Tassin, Tara C.
AU - Mammen, Pradeep P.A.
N1 - Funding Information:
Dr. Pradeep Mammen declares the following conflicts of interests: American Heart Association (AHA) (member of the AHA Career Development Research Grant Committee), California Institute of Regenerative Medicine (member of the Grants Working Group), CareDx Inc. (Site PI for the SHORE Registry), Catabasis Inc. (research grant), NIH (research grants and ad hoc grant reviewer for the NIH MOSS, SMEP, and TDPS Study Sections), Dyne Therapeutics (scientific consultant and member of the Scientific DMD Advisory Board), Novartis Gene Therapies Inc. (member of the Data Monitoring and Safety Committee), PhaseBio Inc. (research grant and member of the Scientific Advisory Board), and Revidia Therapeutics Inc. (member of the Scientific Advisory Board). The other authors have declared that no conflicts of interest exist as it pertains to the subject of the current study.
Funding Information:
This work was supported by the National Institutes of Health (NIH) and the NIH funded UT Southwestern Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center Grant (NIH R01HL102478, U54HD087351, and P50HD087351 awarded to PPAM) and the UT Southwestern Alfred W. Harris, M.D. Professorship in Cardiology (awarded to PPAM).
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022
Y1 - 2022
N2 - Purpose of Review: This review highlights the key studies investigating various types of biomarkers in Duchenne muscular dystrophy (DMD). Recent Findings: Several proteomic and metabolomic studies have been undertaken in both human DMD patients and animal models of DMD that have identified potential biomarkers in DMD. Summary: Although there have been a number of proteomic and metabolomic studies that have identified various potential biomarkers in DMD, more definitive studies still need to be undertaken in DMD patients to firmly correlate these biomarkers with diagnosis, disease progression, and monitoring the effects of novel treatment strategies being developed.
AB - Purpose of Review: This review highlights the key studies investigating various types of biomarkers in Duchenne muscular dystrophy (DMD). Recent Findings: Several proteomic and metabolomic studies have been undertaken in both human DMD patients and animal models of DMD that have identified potential biomarkers in DMD. Summary: Although there have been a number of proteomic and metabolomic studies that have identified various potential biomarkers in DMD, more definitive studies still need to be undertaken in DMD patients to firmly correlate these biomarkers with diagnosis, disease progression, and monitoring the effects of novel treatment strategies being developed.
KW - Biomarkers
KW - DMD-associated cardiomyopathy
KW - Duchenne muscular dystrophy
KW - Metabolomics
KW - Proteomics
UR - http://www.scopus.com/inward/record.url?scp=85127625423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127625423&partnerID=8YFLogxK
U2 - 10.1007/s11897-022-00541-6
DO - 10.1007/s11897-022-00541-6
M3 - Review article
C2 - 35386072
AN - SCOPUS:85127625423
SN - 1546-9530
JO - Current Heart Failure Reports
JF - Current Heart Failure Reports
ER -